title: Optimal therapy of genotype-2 chronic hepatitis C: what's new?
abstract: The standard of care (SOC) for the treatment of HCV genotype 2 (HCV-2) was pegylated interferon alpha plus ribavirin (PEG-IFN/RBV) at weight-based doses for a response-guided duration. The launches of sofosbuvir and daclatasvir in 2014 have resulted in new, better tolerated and shorter treatment. The combination of sofosbuvir and RBV for 12 weeks appears to be the new SOC in both European and American guidelines. The cost and therefore the access to this treatment remains a problem in many countries because of major economic constraints. For the few more difficult-to-treat patients, a combination of direct acting antivirals may be suitable and is being studied in ongoing trials. Because of rapidly changing treatment recommendations, the decision to treat HCV-2 patients with currently approved drugs or to wait until a better option is available in the future, must be made according to the stage of fibrosis.
authors.affiliation: Department of Hepato-Gastroenterology, Hospital Saint Joseph, Marseilles, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
authors.forename: Souad
authors.initials: S
authors.lastname: Benali
authors.forename: Christelle
authors.initials: C
authors.lastname: Ansaldi
authors.forename: Gaelle
authors.initials: G
authors.lastname: Le Folgoc
authors.forename: Aurelie
authors.initials: A
authors.lastname: Riso
authors.forename: Laurence
authors.initials: L
authors.lastname: Lecomte
mesh_terms: D004359:Drug Therapy, Combination / Q000379:methods / Q000639:trends*; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics; D006801:Humans; D015995:Prevalence; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D012254:Ribavirin; D014542:Uridine Monophosphate; D000069474:Sofosbuvir
keywords: AASLD guidelines; European Association for the Study of the Liver guidelines; MK-5172; daclatasvir; genotype 2; hepatitis C virus; ombitasvir; paritaprevir; pegylated interferon alpha; ribavirin; sofosbuvir